[CAS NO. 943609-66-3] Vedolizumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [943609-66-3]

Catalog

HY-P9911

Brand

MCE

CAS

943609-66-3

DESCRIPTION [943609-66-3]

Overview

MDL	-
Molecular Weight	146814.90
Molecular Formula	-
SMILES	[Vedolizumab]

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Anal Chim Acta. 2021, 338306.

Summary

Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

IC50 & Target

Integrin ^[1]

In Vitro

Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC ₅₀ =0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC ₅₀ =0.02-0.06 μg/mL) and fibronectin (IC ₅₀ =0.02 μg/mL), but not vascular cell adhesion molecule 1 ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02674308	Takeda	Ulcerative Colitis and Crohn´s Disease	March 24, 2015
NCT00783718	Millennium Pharmaceuticals, Inc.	Ulcerative Colitis	January 2009	Phase 3
NCT03961308	Takeda	Healthy Volunteers	March 12, 2018	Phase 1
NCT04779307	Takeda	Colitis, Ulcerative	October 19, 2021	Phase 3
NCT05442567	Takeda	Ulcerative Colitis\|Crohn´s Disease	February 28, 2023	Phase 3
NCT03029143	Takeda	Colitis, Ulcerative	March 29, 2017	Phase 4
NCT02723006	Millennium Pharmaceuticals, Inc.\|Takeda	Melanoma	June 22, 2016	Phase 1
NCT04919252	Yonsei University	Crohn´s Disease and Ulcerative Colitis	June 1, 2021	Phase 3
NCT04362735	Pontifícia Universidade Católica do Paraná\|Takeda	Crohn Disease	August 1, 2020
NCT02497469	Takeda	Colitis, Ulcerative	June 29, 2015	Phase 3
NCT03329209	Takeda	Colitis, Ulcerative\|Crohn Disease	March 5, 2018	Phase 1
NCT03802214	Stanford University\|Takeda\|University of Western Ontario, Canada\|University of California, San Diego	Ulcerative Colitis	October 29, 2020
NCT03375424	Ced Service GmbH	Inflammatory Bowel Diseases\|Treatment	October 2, 2017
NCT04006080	Guy´s and St Thomas´ NHS Foundation Trust\|Takeda	Ulcerative Colitis	July 1, 2019	Phase 4
NCT03196427	Takeda\|Takeda Development Center Americas, Inc.	Ulcerative Colitis\|Crohn´s Disease	July 30, 2018	Phase 2
NCT03558152	Genentech, Inc.	Ulcerative Colitis	October 26, 2018	Phase 2
NCT03949621	Takeda	Healthy Volunteers	February 6, 2018	Phase 1
NCT01981616	Millennium Pharmaceuticals, Inc.	Inflammatory Bowel Disease	September 2011	Phase 1
NCT01177228	Millennium Pharmaceuticals, Inc.	Ulcerative Colitis	May 2007	Phase 2
NCT03657160	Millennium Pharmaceuticals, Inc.\|Takeda	Hematopoietic Stem Cells	February 6, 2019	Phase 3
NCT05386290	Peking Union Medical College Hospital	Ulcerative Colitis\|Crohn Disease	July 9, 2020
NCT01224171	Millennium Pharmaceuticals, Inc.	Crohn´s Disease	November 2010	Phase 3
NCT02993783	Millennium Pharmaceuticals, Inc.\|Takeda	Allogeneic Hematopoietic Stem Cell Transplantation	April 28, 2017	Phase 2
NCT05481619	Second Affiliated Hospital, School of Medicine, Zhejiang University	Ulcerative Colitis	January 1, 2021	Phase 4
NCT05158517	Groupe d´Etude Therapeutique des Affections Inflammatoires Digestives\|Takeda	Inflammatory Bowel Diseases	March 20, 2022
NCT02760615	Takeda	Colitis, Ulcerative\|Crohn Disease	November 1, 2016	Phase 4
NCT02630966	Takeda	Crohn´s Disease	August 10, 2016	Phase 4
NCT02712866	Parc de Salut Mar	Inflammatory Bowel Disease	January 2017
NCT03035058	Takeda	Primary Sclerosing Cholangitis\|Inflammatory Bowel Disease	February 2017	Phase 3
NCT02611830	Takeda	Colitis, Ulcerative	December 18, 2015	Phase 3
NCT03885713	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Inflammatory Bowel Diseases\|Crohn Disease\|Ulcerative Colitis	September 10, 2019	Phase 4
NCT03824561	Takeda	Ulcerative Colitis	February 1, 2019
NCT02039505	Takeda	Ulcerative Colitis	February 4, 2014	Phase 3
NCT02820493	Universita degli Studi di Genova	Crohn Disease	September 2016	Phase 4
NCT02611817	Takeda	Crohn´s Disease	January 4, 2016	Phase 3
NCT02646683	Geert D´Haens\|Takeda\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Crohn Disease	July 2015	Phase 4
NCT02790138	Takeda	Pouchitis	October 12, 2016	Phase 4
NCT02878083	Nantes University Hospital\|Takeda\|Mauna Kea Technologies\|Institut National de la Santé Et de la Recherche Médicale, France	ULCERATIVE COLITIS	January 11, 2017	Not Applicable
NCT03221036	Takeda	Moderately to Severely Active Ulcerative Colitis	August 3, 2017	Phase 3
NCT02620046	Takeda	Colitis, Ulcerative\|Crohn´s Disease	April 15, 2016	Phase 3
NCT02972450	ANRS, Emerging Infectious Diseases\|European Commission\|Swiss Government\|Medical Research Council\|FIT Biotech Ltd.\|Fred Hutchinson Cancer Center\|University College, London\|Centre Hospitalier Universitaire Vaudois\|Imperial College London\|Istituto Nazionale Malattie Infettive Lazaro Spallanzani\|Universitätsklinikum Hamburg-Eppendorf\|Institut d´Investigacions Biomèdiques August Pi i Sunyer\|Henri Mondor University Hospital\|European Georges Pompidou Hospital\|Saint-Louis Hospital, Paris, France	HIV-1-infection	February 20, 2019	Phase 1\|Phase 2
NCT02834754	Marc Schwartz\|Takeda\|University of Pittsburgh	Crohn´s Disease	December 1, 2018	Phase 2
NCT02163421	Takeda	Healthy	June 2014	Phase 1
NCT03819296	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Clinical Stage 0 Cutaneous Melanoma AJCC v8\|Clinical Stage I Cutaneous Melanoma AJCC v8\|Clinical Stage IA Cutaneous Melanoma AJCC v8\|Clinical Stage IB Cutaneous Melanoma AJCC v8\|Clinical Stage II Cutaneous Melanoma AJCC v8\|Clinical Stage IIA Cutaneous Melanoma AJCC v8\|Clinical Stage IIB Cutaneous Melanoma AJCC v8\|Clinical Stage IIC Cutaneous Melanoma AJCC v8\|Clinical Stage III Cutaneous Melanoma AJCC v8\|Clinical Stage IV Cutaneous Melanoma AJCC v8\|Colitis\|Lung Non-Small Cell Carcinoma\|Malignant Genitourinary System Neoplasm\|Malignant Solid Neoplasm\|Pathologic Stage 0 Cutaneous Melanoma AJCC v8\|Pathologic Stage I Cutaneous Melanoma AJCC v8\|Pathologic Stage IA Cutaneous Melanoma AJCC v8\|Pathologic Stage IB Cutaneous Melanoma AJCC v8\|Pathologic Stage II Cutaneous Melanoma AJCC v8\|Pathologic Stage IIA Cutaneous Melanoma AJCC v8\|Pathologic Stage IIB Cutaneous Melanoma AJCC v8\|Pathologic Stage IIC Cutaneous Melanoma AJCC v8\|Pathologic Stage III Cutaneous Melanoma AJCC v8\|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8\|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8\|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8\|Pathologic Stage IIID Cutaneous Melanoma AJCC v8\|Pathologic Stage IV Cutaneous Melanoma AJCC v8\|Stage 0 Lung Cancer AJCC v8\|Stage I Lung Cancer AJCC v8\|Stage IA1 Lung Cancer AJCC v8\|Stage IA2 Lung Cancer AJCC v8\|Stage IA3 Lung Cancer AJCC v8\|Stage IB Lung Cancer AJCC v8\|Stage II Lung Cancer AJCC v8\|Stage IIA Lung Cancer AJCC v8\|Stage IIB Lung Cancer AJCC v8\|Stage III Lung Cancer AJCC v8\|Stage IIIA Lung Cancer AJCC v8\|Stage IIIB Lung Cancer AJCC v8\|Stage IIIC Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	February 21, 2021	Phase 1\|Phase 2
NCT02862132	Shaare Zedek Medical Center	Crohn´s Disease\|Ulcerative Colitis\|Inflammatory Bowel Disease	January 2017	Not Applicable
NCT03629379	Universitaire Ziekenhuizen KU Leuven	Inflammatory Bowel Diseases\|Psoriasis	September 1, 2018	Phase 4
NCT04797325	University of Copenhagen	Immune-Mediated Colitis	August 30, 2021	Phase 2
NCT03219359	Aaron Etra\|Icahn School of Medicine at Mount Sinai	Crohn Disease	July 12, 2017	Phase 2
NCT02788175	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	HIV	May 28, 2016	Phase 1
NCT03309865	Mayo Clinic	Ulcerative Colitis\|Dietary Modification	December 25, 2017	Early Phase 1
NCT02953275	University of Miami\|Takeda	Crohn Disease	April 13, 2017	Early Phase 1
NCT03948581	Takeda	Healthy Volunteers	February 21, 2018	Phase 1
NCT02929316	AGA Clinical Research Associates, LLC\|Takeda	Celiac Disease	June 25, 2018	Phase 2
NCT02694588	University Hospital Schleswig-Holstein	IBD	June 2014	Not Applicable
NCT02324699	Icahn School of Medicine at Mount Sinai\|Takeda	Crohn´s Disease	April 2016	Phase 4
NCT03138655	Takeda\|Takeda Development Center Americas, Inc.	Ulcerative Colitis\|Crohn´s Disease	November 8, 2017	Phase 2
NCT02743806	Takeda	Colitis, Ulcerative\|Crohn Disease	August 1, 2016	Phase 4
NCT02646657	Geert D´Haens\|Takeda\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Colitis, Ulcerative	July 2015	Phase 4
NCT04738942	Takeda	Ulcerative Colitis\|Crohn´s Disease	June 4, 2021	Phase 3
NCT02768532	Centre Hospitalier Universitaire de Saint Etienne\|Theradiag\|Takeda	Crohn Disease	July 1, 2016	Phase 4
NCT03234907	Takeda	Crohn´s Disease	August 3, 2017	Phase 3
NCT04002180	Takeda	Crohn´s Disease	July 1, 2019
NCT03237260	University of Pennsylvania\|Takeda\|Corporal Michael J. Crescenz VA Medical Center	Ulcerative Colitis	July 1, 2017	Phase 4
NCT02038920	Takeda	Crohn´s Disease	January 28, 2014	Phase 3
NCT00790933	Takeda	Ulcerative Colitis\|Crohn´s Disease	May 22, 2009	Phase 3
NCT04120415	ANRS, Emerging Infectious Diseases\|EuroVacc Foundation\|European AIDS Treatment Group (EATG)\|Medical Research Council\|University College London Hospitals\|University of Liverpool\|Erasmus Medical Center\|Henri Mondor University Hospital\|European Georges Pompidou Hospital\|Saint-Louis Hospital, Paris, France\|Centre Hospitalier Universitaire Vaudois\|Chelsea and Westminster Hospital, UK\|Universitätsklinikum Hamburg-Eppendorf\|Hospital Clinic of Barcelona\|Istituto Nazionale Malattie Infettive Lazaro Spallanzani\|Imperial College London\|Institut d´Investigacions Biomèdiques August Pi i Sunyer\|European Commission\|Swiss Government	HIV-1-infection	June 21, 2022	Phase 2
NCT02913508	Takeda	Ulcerative Colitis\|Crohn´s Disease	April 2014	Phase 2
NCT02954159	Medical College of Wisconsin\|Takeda	Ulcerative Colitis	May 18, 2017	Phase 3
NCT03961295	Takeda	Healthy Volunteers	February 22, 2018	Phase 1
NCT04804540	Takeda	Ulcerative Colitis\|Crohn Disease	December 29, 2021	Phase 4
NCT03147859	Ottawa Hospital Research Institute\|CHEO Research Institute\|Nebraska Centre for Substance Abuse Research	HIV-infection+AIDS	November 1, 2017	Phase 2
NCT02559713	Takeda	Colitis, Ulcerative\|Crohn´s Disease	November 29, 2017	Phase 4
NCT00783692	Millennium Pharmaceuticals, Inc.	Crohn´s Disease	December 2008	Phase 3
NCT04407247	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Colitis\|Lung Non-Small Cell Carcinoma\|Malignant Genitourinary System Neoplasm\|Malignant Solid Neoplasm\|Melanoma	July 9, 2020	Phase 1\|Phase 2
NCT03142321	Washington University School of Medicine	Crohn Disease of Small Intestine	June 8, 2018	Phase 4
NCT02678052	Takeda\|The Organization of Teratology Information Specialists	Colitis, Ulcerative\|Crohn´s Disease	December 1, 2015
NCT03679546	Rennes University Hospital	Ulcerative Colitis	January 4, 2019	Phase 4
NCT03043677	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Inflammatory Bowel Disease	April 1, 2016
NCT00619489	Millennium Pharmaceuticals, Inc.	Ulcerative Colitis\|Crohn´s Disease	December 2007	Phase 2
NCT04779320	Takeda	Crohn´s Disease (CD)	April 30, 2022	Phase 3
NCT02764762	Takeda	Crohn Disease	June 12, 2017	Phase 4
NCT03577782	Hospitales Universitarios Virgen del Rocío\|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	HIV Infections	September 2018	Phase 1\|Phase 2
NCT05281614	Benaroya Research Institute\|University of California, San Diego	Type 1 Diabetes	August 1, 2022	Early Phase 1
NCT02425111	Takeda	Crohn´s Disease	March 30, 2015	Phase 3
NCT02728895	Takeda	Allogeneic Hematopoietic Stem Cell Transplantation	June 15, 2016	Phase 1
NCT05205603	Sixth Affiliated Hospital, Sun Yat-sen University	Ulcerative Colitis\|Efficacy, Self\|Biologics\|Mesalazine	January 15, 2022	Phase 4
NCT04469062	Eli Lilly and Company	Ulcerative Colitis	April 20, 2021	Phase 3

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.